Brought to you by:
Humacyte completes enrolment in Phase II/III trial of Human Acellular Vessel for vascular trauma repair
Humacyte today announced completion of enrollment in its Phase II/III vascular trauma trial (V005) that is expected to support a Biologics License Application (BLA) filing for the company’s Human Acellular Vessel (HAV) in vascular trauma repair. A press release details…
Humacyte completes enrolment in Phase II/III trial of Human Acellular Vessel for vascular trauma repair
Humacyte today announced completion of enrolment in its Phase II/III vascular trauma trial (V005) that is expected to support a Biologics License Application (BLA) filing for the company’s Human Acellular Vessel (HAV) in vascular trauma repair. A press release details…
Ukrainian surgeons present clinical update on Human Acellular Vessel in vascular trauma at ESVS 2022
Humacyte recently announced the presentation of a clinical update on the Human Acellular Vessel (HAV) for the treatment of vascular trauma. The update was presented by Ukrainian surgeon collaborators, Oleksandr Sokolov (Dnipro State Medical University, Dnipro, Ukraine) and Vasyl Shaprynskyi…
Humacyte provides update on patients treated at front-line hospitals in Ukraine with the Human Acellular Vessel for repair of vascular trauma injuries
Humacyte today announced that the first Ukrainian patients have received implants of the Human Acellular Vessel (HAV) for the treatment of vascular trauma injuries. The implants are part of Humacyte’s humanitarian relief initiative to provide investigational HAVs to multiple front-line…